chartexchange

Kailera Therapeutics Reports Q3 2026 Results: $95.7M Net Loss Highlights Increased R&D Spending

GuruFocus | Nov 4, 2026 5:40 PM EST

Clinical-Stage Biotech's Loss Widens Year-Over-Year as R&D Spending Climbs; Cash Runway Extends Into Mid-2028 Related Stocks: KLRA ,

Read original article